XML 48 R16.htm IDEA: XBRL DOCUMENT
v3.20.1

Stockholders' Equity | 12 Months Ended
--- | ---
Dec. 31, 2019
Equity [Abstract] |
Stockholders' Equity | NOTE 8 – STOCKHOLDERS’ EQUITY 2019 Public Offering of Common Stock and “Pre-Funded” Warrants On December 24, 2019, we closed an underwritten public offering of 32,382,945 shares of common stock at a public offering price of $2.50 per share. In addition, as part of the offering, we sold to an existing investor “pre-funded” warrants to purchase up to an aggregate of 9,017,055 shares of common stock at a purchase price of $2.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant. The gross proceeds to the Company were approximately $103.5 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. There were 9,017,055 “pre-funded” warrants to purchase a total of 9,017,055 shares of common stock outstanding at December 31, 2019. The “pre-funded” warrants are currently exercisable and have no expiration date. 2017 Public Offering of Common Stock On October 19, 2017, we closed an underwritten public offering of 5,750,000 shares of common stock, at a public offering price of $16.00 per share. The gross proceeds to the Company were approximately $92.0 million before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. “Non-Pre-Funded” Warrants “Non-pre-funded” warrants to purchase a total of 70,000 and 1,820,686 shares of common stock were outstanding at December 31, 2019 and 2018, respectively. “Non-pre-funded” warrants to purchase 1,750,686 shares of common stock expired during 2019. We received cash from the exercise of “non-pre-funded” warrants of $0, $3.2 million and $5.9 million during 2019, 2018 and 2017, respectively. The warrants had various exercise prices and terms as follows as of December 31, 2019:
Summary of Warrants |  | Warrants Outstanding |  |  | Exercise Price |  |  | Expiration Date
2015 Financing (a) |  |  | 20,000 |  |  | $ | 6.05 |  |  | July 31, 2020
2015 Financing (b) |  |  | 50,000 |  |  | $ | 11.00 |  |  | May 11, 2020
Total |  |  | 70,000 |  |  |  |  |  |  |
| a) | In connection with the offering on July 31, 2015, the placement agent received warrants to purchase 20,000 shares of common stock at $6.05 per share. The warrants are currently exercisable and expire on July 31, 2020.
| b) | In connection with the offering on May 11, 2015, the placement agent received warrants to purchase 50,000 shares of common stock at $11.00 per share. The warrants are currently exercisable and expire on May 11, 2020.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration